Junshi licenses COVID-19 antibody tech from Lonza
14-07-2020
Danish biotech company secures CRISPR licence
04-06-2019
Charpentier granted new CRISPR/Cas9 patent
23-04-2019
Locus licenses CRISPR tech to Janssen in potential $818m deal
09-01-2019
ralwel / iStockphoto.com
ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CRISPR/cas9, Eric Rhodes, Syngulon, patent dispute, University of California, University of Vienna, Emmanuelle Charpentier
